Go To Global Site
Welcome to UCB in the United States



Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients



Improving Diversity in Dermatology

UCB is participating in the Skin of Color Update (“SOCU”) Dermatology Conference, a forum for medical specialists to discuss trending evidence-based research and best practices for skin of color in dermatology. This year’s SOCU comes at an important time for the healthcare community and serves as an opportunity to have conversations and problem solve around inequities in dermatological care. Read more from Rhonda Peebles, Head of U.S. Dermatology, as she shares her thoughts on racial inequities in dermatology and the steps UCB is taking to move the equity needle forward. 



The Impact of Psoriasis: Infographic

At UCB, we are committed to supporting the psoriasis community and working to improve the future for those living with the disease. In honor of Psoriasis Awareness Month, we’re shining a spotlight on the over 7 million people in the U.S. impacted by psoriasis every day.



Empowering Patients Impacted by Immuno-Dermatological Conditions

At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.